SCHEMBL3638014

SCHEMBL3638014

CCCCCCCCCCCSCC(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 1.00
GMNN O75496 1/20 1.00
TP53 P04637 1/20 1.00
POLB P06746 1/20 1.00
MAPT P10636 1/20 1.00
THRB P10828 1/20 1.00
CYP2C9 P11712 1/20 1.00
BLM P54132 1/20 1.00
CES2 O00748 3/20 0.69
CES1 P23141 5/20 0.60
FAAH O00519 4/20 0.60
PLA2G6 O60733 1/20 0.60
GPR84 Q9NQS5 7/20 0.50
PPARG P37231 7/20 0.50
PPARD Q03181 7/20 0.50
PPARA Q07869 7/20 0.50
HDAC11 Q96DB2 5/20 0.50
TSHR P16473 4/20 0.50
PTPN1 P18031 3/20 0.50
ALDH1A1 P00352 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1405322 1.00 HSD17B10 (1.00) HSD17B10GMNNTP53POLBMAPT
SCHEMBL1405362 1.00 HSD17B10 (1.00) HSD17B10GMNNTP53POLBMAPT
SCHEMBL4814083 1.00 HSD17B10 (1.00) HSD17B10GMNNTP53POLBMAPT
Tetradecylthioacetic Acid SCHEMBL207756 1.00 HSD17B10 (1.00) HSD17B10GMNNTP53POLBMAPT
SCHEMBL1405316 1.00 HSD17B10 (1.00) HSD17B10GMNNTP53POLBMAPT
SCHEMBL1405566 1.00 HSD17B10 (1.00) HSD17B10GMNNTP53POLBMAPT
SCHEMBL939761 1.00 HSD17B10 (1.00) HSD17B10GMNNTP53POLBMAPT
SCHEMBL4354732 1.00 HSD17B10 (1.00) HSD17B10GMNNTP53POLBMAPT
SCHEMBL4649866 1.00 HSD17B10 (1.00) HSD17B10GMNNTP53POLBMAPT
Tetradecylthioacetic Acid SCHEMBL7524926 1.00 HSD17B10 (1.00) HSD17B10GMNNTP53POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265193-A1 PD-1 SIGNAL INHIBITOR COMBINATION THERAPY KYOTO UNIVERSITY (JP) 2023-08-24 US claimed
EP-4218819-A2 COMBINATION THERAPY BASED ON PD-1 SIGNAL INHIBITORS Kyoto University (JP) 2023-08-02 EP claimed
CN-114601930-A Combination therapy of PD-1 signaling inhibitors 国立大学法人京都大学 2022-06-10 CN claimed
US-20180362650-A1 PD-1 SIGNAL INHIBITOR COMBINATION THERAPY KYOTO UNIVERSITY (JP) 2018-12-20 US claimed
EP-3388084-A1 PD-1 SIGNAL INHIBITOR COMBINATION THERAPY Kyoto University (JP) 2018-10-17 EP claimed
CN-108601840-A Combination therapy of PD-1 signaling inhibitors 国立大学法人京都大学 2018-09-28 CN claimed
WO-2025137586-A2 COMPOSITIONS, METHODS, AND SYSTEMS FOR PROMOTING PHOSPHATE SOLUBILIZATION IN PLANTS Tenfold Technologies, LLC (US) 2025-06-26 WO disclosed
US-20230272077-A1 PD-1 SIGNAL INHIBITOR COMBINATION THERAPY KYOTO UNIVERSITY (JP) 2023-08-31 US disclosed
US-20230265193-A1 PD-1 SIGNAL INHIBITOR COMBINATION THERAPY KYOTO UNIVERSITY (JP) 2023-08-24 US disclosed
EP-4218819-A2 COMBINATION THERAPY BASED ON PD-1 SIGNAL INHIBITORS Kyoto University (JP) 2023-08-02 EP disclosed
CN-114601930-A Combination therapy of PD-1 signaling inhibitors 国立大学法人京都大学 2022-06-10 CN disclosed
CN-114404595-A Combination therapy of PD-1 signaling inhibitors 国立大学法人京都大学 2022-04-29 CN disclosed
US-20180362650-A1 PD-1 SIGNAL INHIBITOR COMBINATION THERAPY KYOTO UNIVERSITY (JP) 2018-12-20 US disclosed
CN-108601840-A Combination therapy of PD-1 signaling inhibitors 国立大学法人京都大学 2018-09-28 CN disclosed
US-8263558-B2 Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins ABBOTT LABORATORIES (US) 2012-09-11 US disclosed
EP-2150820-A1 ANALYSIS METHOD Surescreen Diagnostics Limited (GB) 2010-02-10 EP disclosed
US-20090214515-A1 METHODS OF PREPARATION OF RECOMBINANT FORMS OF HUMAN BETA-AMYLOID PROTEIN AND USES OF THESE PROTEINS ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2009-08-27 US disclosed
WO-2008122805-A1 ANALYSIS METHOD SURESCREEN DIAGNOSTICS LIMITED (GB) 2008-10-16 WO disclosed
EP-1963363-A2 METHODS OF PREPARATION OF RECOMBINANT FORMS OF HUMAN BETA-AMYLOID PROTEIN AND USES OF THESE PROTEINS Abbott Laboratories (US) 2008-09-03 EP disclosed
WO-2007064917-A2 METHODS OF PREPARATION OF RECOMBINANT FORMS OF HUMAN BETA-AMYLOID PROTEIN AND USES OF THESE PROTEINS ABBOTT LABORATORIES (US) 2007-06-07 WO disclosed